Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)

LO-NMOSD patients presented more often with myelitis, experienced worse attack outcomes and faster disability accumulation, despite comparable AAR, acute attack treatment and long-term treatment regimens. Accordingly, therapeutic strategies for attack and prophylactic treatment in LO-NMOSD have to be improved.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2025-04-11
DOI
https://doi.org/10.3389/fimmu.2025.1575613
Citations
4
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
5.89

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)

Stefan Gingele, Peter Kern, Ingo Kleiter, Jan‐Patrick Stellmann et al.
4 citations
Frontiers in Immunology
Multiple Sclerosis Research Studies
5.89
article

Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)

Stefan Gingele, Peter Kern, Ingo Kleiter, Jan‐Patrick Stellmann, Brigitte Wildemann, Makbule Şenel, Luisa Klotz, Carolin Schwake, Julian Reza Kretschmer, Achim Berthele, Yavor Yalachkov, Tania Kümpfel, Hayrettin Tumani, Matthias Grothe, Daria Tkachenko, Katrin Giglhuber, Patrick Schindler, Marius Ringelstein, Axel Haarmann, Thivya Pakeerathan, Orhan Aktaş, Markus Kraemer, Judith Bellmann–Strobl, Joachim Havla, Uwe K. Zettl, Friedemann Paul, Felix Luessi, Heike Stephanik, Corinna Trebst, Matthias Kaste, Vivien Häußler, Thorleif Etgen, Jörn Peter Sieb, Klemens Angstwurm, Clemens Warnke, Florian Then Bergh, Martin W. Hümmert, Sven Jarius, Ann-Sophie Lauenstein, Markus C. Kowarik, Ulrike Wallwitz, Antonios Bayas, Christian Geis, Daniel Engels, Patrick Oschmann, Sarah Passoke, Eva Dawin, Ilya Ayzenberg, Veit Rothhammer, Martin S. Weber, Frank Hoffmann, Lisa Revie, Annette O. Walter, Katinka Fischer, Clarissa Zappe
article en
4 citations

Abstract

LO-NMOSD patients presented more often with myelitis, experienced worse attack outcomes and faster disability accumulation, despite comparable AAR, acute attack treatment and long-term treatment regimens. Accordingly, therapeutic strategies for attack and prophylactic treatment in LO-NMOSD have to be improved.

Frontiers in ImmunologyVol. 16
Goethe University Frankfurt (DE), Centre National de la Recherche Scientifique (FR), Universität Hamburg (DE), University of Augsburg (DE), University of Cologne (DE), Friedrich-Alexander-Universität Erlangen-Nürnberg (DE), Universität Ulm (DE), Johannes Gutenberg University Mainz (DE), Max Delbrück Center (DE), Heidelberg University (DE), University of Münster (DE), University of Würzburg (DE), Helios Dr. Horst Schmidt Kliniken Wiesbaden (DE), Bayreuth Medical Center (DE), Medizinische Hochschule Hannover (DE), Universität Greifswald (DE), Deutsche Klinik für Diagnostik (DE), Klinikum Görlitz (DE), University Medical Center Hamburg-Eppendorf (DE), Zentrum Überleben (DE), Herford Hospital (DE), Krankenhaus Nordwest (DE), University Hospital Magdeburg (DE), St. Josef-Hospital (DE), Centre de Résonance Magnétique Biologique et Médicale (FR), Hertie Institute for Clinical Brain Research (DE), Martha-Maria Hospital (DE), University of Applied Sciences Stralsund (DE), Alfried Krupp Hospital (DE), University Hospital Cologne (DE), Asklepios (DE), Hôpital de la Timone (FR), Heinrich Heine University Düsseldorf (DE), University of Rostock (DE), University of Regensburg (DE), Technical University of Munich (DE), University of Göttingen (DE), Friedrich Schiller University Jena (DE), Charité - Universitätsmedizin Berlin (DE), University of Tübingen (DE), Ludwig-Maximilians-Universität München (DE), Leipzig University (DE)
Amgen, Bristol-Myers Squibb, Bayer, GlaxoSmithKline, Sanofi, Biogen, Teva Pharmaceutical Industries, Alexion Pharmaceuticals, Celgene, Guthy-Jackson Charitable Foundation, Argenx, Horizon Therapeutics, Bayer HealthCare, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Friedrich-Baur-Stiftung, Gemeinsame Bundesausschuss, Grifols, Novartis Pharma, Chugai Pharmaceutical, Sanofi Genzyme, Cilag
No poverty
Openalex Percentile: Top 4%
Multiple Sclerosis Research Studies
5.89
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.